NeoGenomics, Inc.
NASDAQ:NEO · NASDAQ Capital Market
+$0.63 today
Vol 6.30M · Avg 1.94M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $146.1M |
| Receivables | $167.4M |
| Inventory | $29.8M |
| Other Current | $30.3M |
| Total Current Assets | $373.7M |
| PP&E (Net) | $160.4M |
| Goodwill | $524.0M |
| Intangible Assets | $278.9M |
| Other Non-current | $9.6M |
| Total Non-current Assets | $972.8M |
| Total Assets | $1.3B |
Analysis
Selected assets total $1.3B for Latest. The largest visible component is Goodwill at $524.0M, about 38.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $159.6M -56.5% | $367.0M +7.2% | $342.5M +30.1% | $263.2M -16.9% | $316.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 -100.0% | $19.8M -72.7% | $72.7M -58.4% | $174.8M -12.0% | $198.6M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $159.2M +5.8% | $150.5M +14.7% | $131.3M +9.7% | $119.7M +6.8% | $112.1M | $533.8M | $399.4M | -$1.7B |
| Inventory | $28.6M +6.8% | $26.7M +10.7% | $24.2M -0.5% | $24.3M +3.8% | $23.4M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $7.4M -36.7% | $11.7M +42.9% | $8.2M +1.5% | $8.1M -55.7% | $18.2M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $376.3M -36.9% | $596.0M -0.1% | $596.8M -1.4% | $605.3M -11.2% | $681.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $163.3M -6.0% | $173.7M -5.5% | $183.8M -7.5% | $198.6M -6.2% | $211.7M | $1.2B | $1.5B | $687.8M |
| Goodwill | $524.3M +0.3% | $522.8M +0.0% | $522.8M +0.0% | $522.8M -0.8% | $527.1M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $286.5M -15.6% | $339.7M -9.0% | $373.1M -8.6% | $408.3M -7.7% | $442.3M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 -100.0% | $31.0K -86.9% | $236.0K | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 -100.0% | $34.8M -37.4% | $55.5M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $9.4M +59.6% | $5.9M +24.1% | $4.7M +116.0% | -$29.7M +38.9% | -$48.5M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $983.5M -5.6% | $1.0B -3.9% | $1.1B -4.4% | $1.1B -4.5% | $1.2B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $1.4B -17.0% | $1.6B -2.6% | $1.7B -3.4% | $1.7B -6.9% | $1.9B | $13.3B | $11.9B | $10.6B |
| Account Payables | $23.1M +6.9% | $21.6M +6.3% | $20.3M -0.9% | $20.5M +14.4% | $17.9M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $4.8M -97.6% | $200.8M | $0 | $0 -100.0% | $1.1M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 -100.0% | $409.0K -80.8% | $2.1M -71.8% | $7.6M +45.6% | $5.2M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $60.4M -3.2% | $62.4M +17.5% | $53.2M +252.8% | $15.1M -9.5% | $16.7M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $88.3M -70.7% | $301.2M +212.8% | $96.3M +7.1% | $89.9M +3.1% | $87.2M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $404.7M +18.9% | $340.3M -36.8% | $538.2M +0.5% | $535.3M +0.5% | $532.5M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $18.2M -15.3% | $21.5M -11.4% | $24.3M -30.1% | $34.8M -37.4% | $55.5M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $386.0K | $0 | $0 -100.0% | $19.0K -97.9% | $917.0K | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$51.1M -534.4% | $11.8M -9.7% | $13.0M -0.2% | $13.1M +0.2% | $13.0M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $435.0M +0.1% | $434.5M -32.5% | $643.4M -1.3% | $652.1M -3.3% | $674.3M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $523.3M -28.9% | $735.7M -0.5% | $739.7M -0.3% | $742.0M -2.6% | $761.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $129.0K +0.8% | $128.0K +0.8% | $127.0K +0.0% | $127.0K +2.4% | $124.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$433.8M -33.2% | -$325.8M -31.9% | -$247.1M -55.3% | -$159.1M -972.2% | -$14.8M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $4.0K +101.9% | -$206.0K +87.7% | -$1.7M +57.1% | -$3.9M -511.1% | -$638.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $836.6M -7.3% | $902.3M -4.2% | $941.5M -5.7% | $998.0M -9.9% | $1.1B | $9.1B | $7.7B | $3.3B |
| Total Debt | $472.3M -22.0% | $605.3M -1.0% | $611.7M +0.1% | $610.9M -0.3% | $612.8M | $724.2M | $410.6M | $399.4M |
| Net Debt | $312.7M +31.2% | $238.3M -11.5% | $269.2M -22.6% | $347.7M +17.5% | $296.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$533.63M
Alpha Teknova, Inc.
NASDAQ:TKNO
$277.45M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$216.99M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$211.61M
Sanara MedTech Inc.
NASDAQ:SMTI
$198.81M
Stereotaxis, Inc.
AMEX:STXS
$178.37M
Humacyte, Inc.
NASDAQ:HUMA
$156.07M
Quanterix Corporation
NASDAQ:QTRX
$152.86M
Exagen Inc.
NASDAQ:XGN
$105.58M
MDxHealth S.A.
MDXH
$28.53M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does NEO have?
NeoGenomics, Inc. (NEO) reported $159.62M in cash and equivalents in fiscal 2025.
How much debt does NEO carry?
NeoGenomics, Inc. (NEO) reported $472.28M of total debt, with net debt of $312.66M.
Explore More
Continue the stock analysis
Jump to another research area for this company.